Last night's "In Our Genes: An Evening of Storytelling" was an event that not only raised money for research in BRCA-related cancers, but also aimed to raise the spirits of individuals who have been affected by the gene mutation.
CURE spoke with an expert on the future of treating triple-negative breast cancer, including the potential for immunotherapy, targeted therapy and AR-targeted agents.
Optimizing treatment for patients with HR-positive breast cancer means that researchers must first find a way for patients to overcome drug resistance, says William J. Gradishar, M.D.